Alain Lafeuillade

3.3k total citations
89 papers, 1.7k citations indexed

About

Alain Lafeuillade is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Alain Lafeuillade has authored 89 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Infectious Diseases, 55 papers in Virology and 20 papers in Emergency Medicine. Recurrent topics in Alain Lafeuillade's work include HIV Research and Treatment (55 papers), HIV/AIDS drug development and treatment (45 papers) and HIV/AIDS Research and Interventions (36 papers). Alain Lafeuillade is often cited by papers focused on HIV Research and Treatment (55 papers), HIV/AIDS drug development and treatment (45 papers) and HIV/AIDS Research and Interventions (36 papers). Alain Lafeuillade collaborates with scholars based in France, United States and Spain. Alain Lafeuillade's co-authors include Cécile Poggi, Gilles Hittinger, N. Profizi, Philippe Halfon, Bruno Lacarelle, Caroline Solas, Catherine Tamalet, Jean‐Paul Viard, Thiérry Prazuck and Bernard Cardon and has published in prestigious journals such as The Journal of Immunology, Hepatology and Journal of Clinical Microbiology.

In The Last Decade

Alain Lafeuillade

84 papers receiving 1.7k citations

Peers

Countries citing papers authored by Alain Lafeuillade

Since Specialization

Citations

This map shows the geographic impact of Alain Lafeuillade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Lafeuillade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Lafeuillade more than expected).

Fields of papers citing papers by Alain Lafeuillade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain Lafeuillade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Lafeuillade. The network helps show where Alain Lafeuillade may publish in the future.

Co-authorship network of co-authors of Alain Lafeuillade

This figure shows the co-authorship network connecting the top 25 collaborators of Alain Lafeuillade. A scholar is included among the top collaborators of Alain Lafeuillade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alain Lafeuillade. Alain Lafeuillade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Are current guidelines adapted for patient eligibility to PrEP? A case report 2019 ·BMC Infectious Diseases ·(unknown), (unknown), Alain Lafeuillade, (unknown), Fanny Rocher, Milou‐Daniel Drici	0
2	Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial 2016 ·AIDS Research and Therapy ·(unknown), Nathalie De Castro, Joséphine Braun, Isabelle Charreau, Alain Lafeuillade, Jean‐Paul Viard, Clotilde Allavena, J Aboulker, Jean‐Michel Molina	9
3	Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic 2014 ·AIDS Research and Therapy ·Alain Lafeuillade, Mark A. Wainberg, Marie‐Lise Gougeon, Sabine Kinloch‐de Loes, Philippe Halfon, Hervé Tissot‐Dupont	1
4	Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: A prospective multicenter cohort 2014 ·Clinics and Research in Hepatology and Gastroenterology ·Philippe Halfon, Denis Ouzan, Tarik Asselah, Christophe Renou, Thierry Allègre, (unknown), Alain Lafeuillade, Jean–François Cadranel, (unknown), Hacène Khiri, Guillaume Pénaranda, Marc Bourlière	1
5	Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection 2010 ·AIDS ·Laurent Hocqueloux, Thiérry Prazuck, Véronique Avettand-Fènoël, Alain Lafeuillade, Bernard Cardon, Jean‐Paul Viard, Christine Rouzioux	149
6	Hepatitis E virus in HIV-infected patients 2010 ·AIDS ·Christophe Renou, Alain Lafeuillade, Jean–François Cadranel, Nicole Pavio, Alexandre Pariente, Thierry Allègre, Cécile Poggi, Guillaume Pénaranda, (unknown), Élisabeth Nicand	53
7	HIV-1 Meningoencephalitis in Patients on Effective HAART 2009 ·HIV Clinical Trials ·Alain Lafeuillade, Antoine Chéret, Gilles Hittinger, Cécile Poggi	2
8	Rectal Cell-Associated HIV-1 RNA: A New Marker Ready for the Clinic 2009 ·HIV Clinical Trials ·Alain Lafeuillade, Antoine Chéret, Gilles Hittinger, David Bernardini, (unknown), Eric Jullian, Cécile Poggi	11
9	Predictors of Plasma Human Immunodeficiency Virus Type 1 RNA Control after Discontinuation of Highly Active Antiretroviral Therapy Initiated at Acute Infection Combined with Structured Treatment Interruptions and Immune‐Based Therapies 2003 ·The Journal of Infectious Diseases ·Alain Lafeuillade, Cécile Poggi, Gilles Hittinger, E. Counillon, D Émilie	42
10	TRIZAL study: switching from successful HAART to Trizivir^TM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results 2003 ·HIV Medicine ·Christine Katlama, (unknown), Brian Gazzard, Adriano Lazzarin, Nathan Clumeck, Josep Mallolas, Alain Lafeuillade, (unknown), (unknown)	66
11	Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations 2002 ·HIV Clinical Trials ·Alain Lafeuillade, Caroline Solas, Philippe Halfon, (unknown), Gilles Hittinger, Bruno Lacarelle	64
12	HIV-1 Induction-Maintenance at the Lymph Node Level: The “Apollo-97” Study 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Alain Lafeuillade, Cécile Poggi, (unknown), Gilles Hittinger, (unknown), (unknown)	1
13	Peripheral neuropathy during stavudine‐didanosine antiretroviral therapy 2001 ·HIV Medicine ·Véronique Reliquet, (unknown), (unknown), Alain Lafeuillade, François Raffi	16
14	Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients 1998 ·Infection ·Gilles Hittinger, Cécile Poggi, (unknown), N. Profizi, Alain Lafeuillade	33
15	Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients 1998 ·AIDS ·François Raffi, Véronique Reliquet, (unknown), Jean‐Marc Besnier, Jean-Marie Chennebault, Éric Billaud, C. Michelet, Philippe Van de Perre, Alain Lafeuillade, Thierry May, Sylviane Billaudel	18
16	Quantification of HIV-1 viral load in lymphoid and blood cells 1997 ·AIDS ·Catherine Tamalet, Alain Lafeuillade, Jacques Fantini, Cécile Poggi, Nouara Yahi	55
17	Assessment of a standardized reverse-transcriptase PCR assay for quantifying HIV-1 RNA in plasma and serum 1996 ·Journal of Virological Methods ·Jacques Izopet, Cécile Poggi, Élisabeth Dussaix, Jean‐Michel Mansuy, (unknown), N. Profizi, Alain Lafeuillade, B. Marchou, Patrice Massip, Chalom Sayada, J Puel	12
18	HIV-1 replication in the plasma and cerebrospinal fluid 1996 ·Infection ·Alain Lafeuillade, (unknown), Cécile Poggi, (unknown), N. Profizi, Chalom Sayada	18
19	Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood 1994 ·AIDS ·Catherine Tamalet, Alain Lafeuillade, Nouara Yahi, C. Vignoli, Christian Tourrès, Pierre Pellegrino, Philippe de Micco	23
20	OEDEME ANGIONEUROTIQUE ACQUIS AU COURS D'UNE LEUCEMIE LYMPHOIDE CHRONIQUE : UNE OBSERVATION 1993 ·La Presse Médicale ·Alain Lafeuillade, (unknown), R Quilichini	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact